Exploring the Therapeutic Potential of Cardamom to Attenuate the Physiological Dysfunctions
INTERNATIONAL SEMINAR-2022
Dr. Ayesha Murtaza (Ph.D.)
Assistant Professor
University of Central Punjab (UCP),PAKISTAN
PRESENTED AT
Nutrition Health Polytechnic Ministry of Health Tasikmalaya
Contents:
2
PART ONE
INTRODUCTION
3
Nutrition and Immunity
4
What Is Our Immune System?
Innate immunity
Adaptive or acquired immunity
5
Cardamom
6
7
Nature of plant
8
Cardamom
9
Cardamom
10
Other Names
11
Types of Cardamom
12
13
14
Bioactive Components
15
Active ingredients | Amount |
1,8-cineole | 21.4% |
Terpinolene | 8.6% |
α-terpinyl acetate | 42.3% |
Linalyl acetate | 8.2% |
Limonene | 5.6% |
Myrcene | 6.6% |
Anticholinesterase activity
Neuroprotective effect
Flavor Profile
(Karibasappa, 1987)
16
Therapeutic Potential
17
Therapeutic Potential
18
Flavor Destruction
(Brennand and Heinz, 2018)
19
Flavor Destruction
20
Objectives
21
Contents:
22
PART TWO
Review of Literature
Review of Literature
23
Review of Literature
24
Review of Literature
(Zhao et al., 2006)
25
Review of Literature
26
Review of Literature:
27
28
Condition | Treatment (Dose/Duration) | Outcome | References | ||
SD | Trend | NE | |||
TABLE 1 - Green Cardamom Effects in Human Studies
T2DM | Seed powder (3 g/d; 8 wk)�All groups consumed with 3 glasses black tea�n = 39–42/group(gp) | Versus baseline | ↓WC, ↓FBG | BW, BMI, HbA1c, BP, blood lipids, I-CAM-1 | 19,20 |
Seed powder (3 g/d; 10 wk)�n = 37–38/gp | Versus placebo:�↓HbA1c, ↓SI, ↓HOMA-IR, ↓TG, ↑SIRT1 | | BMI, WC, FBG, HDL, LDL, TC | 21 | |
Overweight/obese prediabetic women | Seed powder (3 g/d; 2 mo)�n = 40/gp | Versus placebo:�↓CRP, ↓MDA, ↓WC | ↓TC, ↓LDL, ↓HOMA-IR, ↑HDL, ↑TNF-α, ↓TAC | TG, FBG, SI, IL-6, QUICKI, BMI, BW, BP, RBS-SOD, RBS-GR | 22–24 |
Overweight/obese NAFLD | Seed powder (3 g/d; 3 mo)�n = 43–44/gp | Versus placebo:�↓TG, ↑HDL, ↓SI, ↓HOMA-IR, ↓fatty liver, ↑irisin, ↑SIRT1, ↓CRP, ↓IL-6↓TNF-α, ↓ALT | ↓LDL, | FBG, BW, BMI, TC, AST | 25,26 |
Overweight/obese women PCOS | Seed powder (3 g/d; 4 mo)�All groups consumed low-calorie diet�n = 95–99/gp | Versus placebo:�↓BMI, ↓%body fat, ↓TNF-α, ↓IL-6, ↓PBMC-CRP, ↓ovarian cysts, ↓androstenedione, ↓DHEA, ↓T, ↓LH, ↑FSH | ↓PBMC–TNF-α | WC, TSH, CRP, PBMC-IL-6r | 27 |
29
TABLE 1 - Green Cardamom Effects in Human Studies
Atherosclerotic, overweight women | Rhizome powder-containing functional beverage (3 g/d; 2 mo)�Controls consumed functional beverage minus rhizome�n = 10/gp | Versus placebo:�↓IL-6, ↓CRP | ↓TC, ↓LDL, ↑HDL | TG | 11 |
Pregnant women, <22 wk gestational age, mild to moderate nausea + vomiting | Seed powder (1.5 g/d; 4 d)�n = 60/gp | Versus placebo:�↓severity nausea + vomiting | | | 28 |
Hypertensives | Seed powder (3 g/d; 3 mo)�n = 20; no controls) | Versus baseline:�↓SBP, ↓DBP, ↑TAC, ↑blood fibrinolytic activity | ↓TC, ↓TG, ↓LDL, ↓VLDL | Fibrinogen activity, HDL | 29 |
Healthy women | Arabic coffee, unfiltered. Prepared in boiling water (parts ground coffee to parts seed powder) = 3:0, 3:1, 3:2�(500 mL/d, 5 d/wk; 4 wk)�n = 10–13/gp | Versus baseline: ↑TC, ↓GGT | | BP, CRP, AST, ALT, CK, LDH, TG, LDL, HDL, BP, CRP, AST, ALT, CK, LDH | 30 |
Condition | Treatment (Dose/Duration) | Outcome | References | ||
SD | Trend | NE | |||
30
TABLE 2 - Summary of Green Cardamom Effects in Animal Models
Condition | Treatments Dose/Duration | Outcomes | References |
Blood glucose/lipid dysregulation | Seed powder 1%–7% w/w diet; 4–8 wk | ↓FBG, ↓LDL, ↓SBP, ↓SI, ±TC, ±TG, ±HDL, ±ALP, ↑blood + tissue antioxidants, improved liver morphology | 36–39 |
Seed volatile oil 0.3% diet; 8 wk | ↓TC, ↓LDL, ↓TG, ↓heart TC, ↑blood antioxidants, ↓blood + liver + heart LPO�NE: HDL | 38 | |
Seed extract (alcoholic SCCO2) 55–1000 mg/kg per day PO; 1–8 wk | ↓TC, ↓TG, ↓LDL, ↓SI, ↓AI, ↓FBG, ↓HOMA-IR, ↑HDL, improved liver + kidney morphology | 40–44 | |
Leaf extract (alcoholic) 100 mg/kg per day PO; 2 wk | ↓FBG, ↓TC | 45 | |
Rhizome extract (alcoholic) 100 mg/kg per day PO; 2 wk | ↓MDA, ↑SOD, ↓CRP, ↓IL-6 | 46 | |
GI + kidney health | Seed extract (aqueous) | | |
1–10 μg/mL; acute perfusion | ↑Gastric acid secretion�↓MgSO4-induced diarrhea | 47 | |
10 mL/kg PO; acute | NE: BaSO4- and castor oil-induced diarrhea | 48 | |
Seed extract (alcoholic)�100–500 mg/kg PO; 1–4 h�1–10 mg/kg IP; 6 h | ↓Ethanol- and aspirin-induced gastric lesions�↑Urine vol, ↑Na+/K+ excretion | 49,50�51 | |
Seed extract (petroleum ether) 12.5–150 mg/kg PO; 1–4 h | ↓Ethanol- and aspirin-induced gastric lesions | 49,50 | |
Seed volatile oil 12.5–150 mg/kg PO; 1–4 h | ↓Ethanol- and aspirin-induced gastric lesions | 49,50 | |
Inflammation + pain | Seed volatile oil | | |
133–400 μL/kg IP; 1 h | ↓Carrageenan-induced paw edema, ↑analgesic activity | 52 | |
10 mg/mL PO; 1 h | NE: carrageenan-induced paw edema | 53 | |
0.3% w/w diet; 1 mo | NE: carrageenan-induced paw edema | 53 | |
Seed extract (hexane) 50–100 mg/kg IP; acute | ↓Carrageenan-induced paw edema�↓Paw tissue levels of COX-2 + IL-6 + TNF-α + iNOS-mediated NO generation�↑SOD, ↑CAT, ↑GSH | 54 | |
Seed powder�5% w/w diet; 1 mo | NE: carrageenan-induced paw edema | 53 | |
| | 53 | |
| | | 77 |
31
TABLE 2 - Summary of Green Cardamom Effects in Animal Models
Condition | Treatments Dose/Duration | Outcomes | References |
Cancer | Seed powder | | |
0.5 mg/d PO; 8 wk | ↓Chemical-induced colonic ACF, ↓colon cell proliferation, ↓colon COX-2 + iNOS expression, ↑colon + liver GST, ↓colon + liver LPO | 55,56 | |
0.5 mg/d PO; 16 wk | ↓Chemical-induced skin cancer, ↓liver LPO, ↑liver GSH | 57 | |
500 mg/kg PO; 12 wk | ↓Chemical-induced skin cancer, ↓skin TBARS + COX-2, ↓skin Nrf-2 expression + Keap-1 expression, ↑skin GSH + GPx + SOD + CAT | 58 | |
500 mg/kg PO; 24 wk | ↓Chemical-induced stomach cancer, ↑liver GST + GPx + SOD + CAT + GSH, ↓liver LPO | 59 | |
Seed extract (alcoholic) 100 mg/kg PO; 10 d | ↓Ehrlich ascites tumor weight + size�↑Tumor SOD + GPx + mRNA expression of Bax + caspase-3/caspase-8/caspase-9 | 60 | |
Seed volatile oil 100–200 mg/kg PO; 24 wk | ↓Chemical-induced liver cancer�↓TNF-α, ↓IL-1β, ↓AFP, ↓ALT, ↓AST�↑Liver SOD + CAT + GSH + GPx + GR | 61 |
Neurological function | 100–400 mg/kg PO; 8 wk | ↓Diabetes-induced learning and memory deficits, ↓brain Aβ1–42 deposits + p-tau–positive cells + AChE + GSK-3β | 42 |
200–800 mg/kg IP; 30 min | ↓Anxiety-like behavior | 72 | |
Seed powder | | | |
10%–20% w/w diet; during pregnancy to postnatal 15 d | Offspring: ↑learning and memory, ↓eye opening, ↓neuromotor maturation, ↓weight gain, ↑forebrain 5-HT + DA | 73 | |
5%–20% w/w diet; during pregnancy to postnatal 22 d | Offspring: ↓weight gain + eye opening�♂: ↑Aggressive behavior�♀: ↓Aggressive behavior | 74 | |
10%–20% w/w diet; during pregnancy to postnatal 15 d | Offspring: ↑nonsocial threat and attack behavior, ↓social and defense behaviors + motor activity�♂: ↑Progesterone�♀: ↑Testosterone | 75 |
32
TABLE 2 - Summary of Green Cardamom Effects in Animal Models
Condition | Treatments Dose/Duration | Outcomes | References |
Infection | Seed volatile oil 258 mg/kg PO; 6 d | ↓Intestinal burden of bacterial pathogens, ↓inflammation, ↓proinflammatory mediators in intestine, kidney, and lungs | 76 |
Toxicity | Seed extract (aqueous) | | |
100–200 mg/kg PO; 30 d | ↓Chemical-induced myocardial injury, ↓myonecrosis, ↓edema, ↓inflammation | 62 | |
100–200 mg/kg PO; 3 wk | ↓Gentamycin-induced kidney damage, ↓serum urea + creatinine | 63 | |
200 mg/kg PO; 5 wk | ↓DOX cardiotoxicity, ↓heart apoptosis + oxidative stress + inflammation, ↑heart angiogenesis | 64 | |
Seed extract (alcoholic) | | | |
250–1000 mg/kg PO; 15 d | ↓Chemical-induced amnesia. ↓brain LPO, ↑brain GSH + CAT + SOD | 65 | |
Seed extract (ethyl acetate) 100–200 mg/kg PO; 5 wk | ↓CCl4-induced liver injury, ↓GPT, ↓GOT, ↓ALP, ↓liver LPO, ↑liver SOD, ↑liver GST + SOD gene expression | 67 | |
Seed volatile oil | | | |
5–100 mg/kg PO; 13 d | ↓DOX-induced immunosuppression, ↑WBCs, ↑CD4+ cells, and CD8+ cells | 68 | |
100–200 mg/kg PO; 42 d | ↓Al-induced neurotoxicity, ↓behavioral deficits, ↓brain AChE + oxidative stress + amyloid β plaque | 69 | |
Seed powder | | | |
0.2% w/w diet; 12 mo | ↓Pan masala–induced lung injury | 70 | |
0.2% w/w diet; 9 mo | ↓Pan masala–induced testicular damage | 71 |
Review of Literature
Side effects:
33
Conclusion
34
Future Perspectives:
35
Changes in enzymatic activity of polyphenol oxidase (PPO) and its structural modification in apple juice subjected to high pressure carbon dioxide (HPCD)
INTERNATIONAL SEMINAR-2022
Dr. Ayesha Murtaza (Ph.D.)
Assistant Professor
University of Central Punjab (UCP),PAKISTAN
PRESENTED AT
Nutrition Health Polytechnic Ministry of Health Tasikmalaya
Apple Juice
Problem during juice processing
Polyphenol oxidase
Thermal and non-thermal Technologies
PART ONE
INTRODUCTION
38
Explored the effects of different phases of carbon dioxide under HP-CO2 treatment on aggregation, conformational changes and inactivation mechanism of polyphenol oxidase from apple juice.
To study the comparison of thermal and HP-CO2 treatment on quality and stability of apple juice.
To investigate the aggregation, conformational changes and inactivation mechanism of polyphenol oxidase enzyme in apple juice after thermal treatment
Characterization of phenolic profile using HPLC from apple juice after thermal and HP-CO2 treatment.
Research Objectives
01
02
04
03
39
Mostly consumers prefer minimal processed fruit juices with good nutritional value, natural appearance and fresh like characteristics without adding preservatives
Apple Juice
40
Endogenous Enzymes
Polyphenol oxidase (PPO)
Peroxidase (POD)
Pectin methylesterase (PME)
PPO-the major culprit
Apple, Pear, Peach, Mango, Strawberries, avocados, lettuce, potatoes
Browning
Enzymatic
Non-Enzymatic
Oxidation of phenolic compounds
Sensory properties
Bad
Problems during juice processing
41
42
Polyphenol Oxidase (PPO)
43
Structure of PPO protein
44
Structure-PPO protein
Active site of PPO
ThermalMethod
45
46
Non-thermal processing
47
NONTHERMAL
PROCESSING
Shelf Life Extension
Innovative Fresh Products
Minimally Processed
Green Technology
Unwanted Enzyme Inactivation
Pathogen Inactivation
High pressure carbon
dioxide (HPCD)
Pulsed electric field
Ultrasonic processing
Non-thermal
Processing
Emerging Non-thermal processing
48
49
HPCD
Method
50
Factors affecting enzyme inactivation by HPCD
51
METHODOLOGY
Apple juice
HPCD treatment
CD spectral Analysis
Fluorescence analysis
Quality Attributes
Electrophoresis analysis
PPO Extraction & Purification
Structural Analysis
PPO activity Assay
BD Analysis
Color Measurement
pH
TSS
PSD Analysis
52
Effect of HPCD on the activity of crude PPO
Fig. 1. (A) Residual activity of PPO (%).
RESULTS
53
Browning degree of HPCD treated juice during storage
Fig. 2. Browning degree during storage at 4 °C.
54
pH, △E and brix of apple juice after HPCD treatment
Parameter | Control | 25 °C 5MPa | 40 °C 5MPa | 25 °C 10MPa | 31.1 °C 7.38 MPa | 40 °C 10MPa | 40 °C 25MPa | 55 °C 25MPa |
pH | 3.60±0.05a | 3.60±0.11a | 3.58±0.01a | 3.61±0.02a | 3.62±0.056a | 3.56±0.02a | 3.58±0.051a | 3.59±0.03a |
△E | 6.87±0.03a | 6.71±1.76a | 5.97±0.15b | 4.93±0.08c | 3.30±0.73d | 3.22±0.12d | 2.91±0.57e | 2.03±0.40f |
Brix° | 10.25±0.18a | 10.22±0.83a | 10.25±0.57a | 10.25±1.21a | 10.25±0.01a | 10.25±0.05a | 10.26±0.5a | 10.24±0.12a |
55
Effect of HPCD on the PSD analysis
8.23 %
29.8 %
Dissociation
Aggregation
36.6 %
Fig. 2. Dynamic light scattering analysis showed particle size distribution (PSD) pattern of native and HPCD-treated PPO.
Effect of HPCD on the secondary structure
Fig. 3. Circular dichroism (CD) spectra of the native and HPCD -treated PPO.
56
57
Effect of HPCD on the tertiary structure of PPO
Critical state dramatically decreased the fluorescence intensity at λmax of 312
induced evident blue shifts
RESULTS
Fig. 4. Fluorescence spectra of native and HPCD treated PPO at various treatments showing correlation analysis between blue shift and inactivation rate.
Secondary structure contents
Treatments | Secondary Structure contents (%) | |||
α-Helix | β-sheet | β-turn | Random coil | |
Native | 23.56±0.61a | 40.81±1.43c | 18.41±0.98c | 17.22±0.64c |
25 °C 10 MPa | 20.42±0.40b | 41.21±1.03b | 19.44±1.56b | 18.93±1.31b |
31.1 °C 7.38 MPa | 12.21±0.73c | 43.11±0.62ab | 21.85±0.42ab | 22.83±1.87ab |
55 °C 25 MPa | 10.50±1.49d | 44.12±0.35a | 22.01±0.20a | 23.37±0.98a |
x
RESULTS
58
59
(I) SDS-PAGE); (II) Native PAGE stained with Coomassie Brilliant Blue R-250; (III) Native PAGE stained with catechol.
Super-critical state showed complete loss of enzyme activity because of protein degradation
Native
25 °C,10 MPa
31.1 °C,7.38 MPa
55 °C,25 MPa
Native
25 °C,10 MPa
31.1 °C,7.38 MPa
55 °C,25 MPa
Native
25 °C,10 MPa
31.1 °C,7.38 MPa
55 °C,25 MPa
60
Proposed Mechanism of PPO by HPCD inactivation
61
Conclusion
62
Conclusion
Future Directions
FUTURE DIRECTIONS
51
64
FUTURE DIRECTIONS
52
65
Publications
66
67
67
68